CO2020003475A2 - Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos - Google Patents

Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos

Info

Publication number
CO2020003475A2
CO2020003475A2 CONC2020/0003475A CO2020003475A CO2020003475A2 CO 2020003475 A2 CO2020003475 A2 CO 2020003475A2 CO 2020003475 A CO2020003475 A CO 2020003475A CO 2020003475 A2 CO2020003475 A2 CO 2020003475A2
Authority
CO
Colombia
Prior art keywords
methods
compounds
sulfoxides
sulfones
bicyclic
Prior art date
Application number
CONC2020/0003475A
Other languages
English (en)
Inventor
Craig Stivala
Blake Daniels
Snahel Patel
Huifen Chen
Gregory Hamilton
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2020003475A2 publication Critical patent/CO2020003475A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Abstract

La invención proporciona nuevos compuestos que tienen la fórmula general I: en donde R1, RB1, RB2, n, p, q, el anillo A y el anillo B son como se describen en el presente documento, composiciones farmacéuticas que incluyen los compuestos y métodos para usar los compuestos. Los compuestos de formula (I) son inhibidores de RIP1 quinasa y por lo tanto útiles en el tratamiento de enfermedades inflamatorias, neurodegenerativas y de otro tipo.
CONC2020/0003475A 2017-10-31 2020-03-25 Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos CO2020003475A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579392P 2017-10-31 2017-10-31
PCT/EP2018/079772 WO2019086494A1 (en) 2017-10-31 2018-10-30 Bicyclic sulfones and sulfoxides and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2020003475A2 true CO2020003475A2 (es) 2020-04-24

Family

ID=64051580

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0003475A CO2020003475A2 (es) 2017-10-31 2020-03-25 Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos

Country Status (21)

Country Link
US (2) US11072617B2 (es)
EP (1) EP3704097B1 (es)
JP (1) JP2021501183A (es)
KR (1) KR20200083515A (es)
CN (1) CN111278809A (es)
AR (1) AR113811A1 (es)
AU (1) AU2018360270A1 (es)
BR (1) BR112020008446A2 (es)
CA (1) CA3078688A1 (es)
CL (1) CL2020001062A1 (es)
CO (1) CO2020003475A2 (es)
CR (1) CR20200168A (es)
IL (1) IL273847A (es)
MA (1) MA50503A (es)
MX (1) MX2020003451A (es)
PE (1) PE20211247A1 (es)
PH (1) PH12020550537A1 (es)
RU (1) RU2020115915A (es)
SG (1) SG11202002877RA (es)
TW (1) TW201922748A (es)
WO (1) WO2019086494A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
CA3067944C (en) 2017-07-14 2023-03-14 F. Hoffmann-La Roche Ag Bicyclic ketone compounds and methods of use thereof
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
WO2023083847A1 (en) 2021-11-11 2023-05-19 Sanofi Isoxazolidines as ripk1 inhibitors and use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) * 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
CA2141216A1 (en) 1992-07-27 1994-02-03 Michael J. Micklus Targeting of liposomes to the blood-brain barrier
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
EP1007042A4 (en) 1997-06-13 2001-07-04 Sugen Inc NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2494700C (en) 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
AU2003302676A1 (en) 2002-12-03 2004-06-23 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
CA2524269A1 (en) 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
EP2083009A1 (de) 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2773640B1 (en) 2011-11-03 2015-08-19 Hoffmann-La Roche AG Bicyclic piperazine compounds
KR20150023445A (ko) 2012-05-22 2015-03-05 에프. 호프만-라 로슈 아게 치환된 다이피리딜아민 및 이의 용도
CA2896187A1 (en) 2013-01-18 2014-07-24 F. Hoffmann-La Roche Ag 3-substituted pyrazoles and use as dlk inhibitors
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
WO2014177524A1 (en) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
PE20200447A1 (es) 2013-05-01 2020-02-28 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
US10233191B2 (en) 2013-07-10 2019-03-19 Vertex Pharmaceuticals Incorporated Fused piperidine amides as modulators of ion channels
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
UA119347C2 (uk) 2014-03-26 2019-06-10 Ф. Хоффманн-Ля Рош Аг Конденсовані [1,4]діазепінові сполуки як інгібітори продукції аутотаксину (atх) та лізофосфатидилової кислоти (lpa)
WO2016027253A1 (en) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
CN107406462B (zh) 2015-03-09 2020-11-10 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
PE20221048A1 (es) * 2015-07-02 2022-06-30 Hoffmann La Roche Lactamas biciclicas como inhibidores de rip1 cinasa
WO2017096301A1 (en) * 2015-12-04 2017-06-08 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1)
WO2017109724A1 (en) * 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN109071504B (zh) * 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CA3067944C (en) 2017-07-14 2023-03-14 F. Hoffmann-La Roche Ag Bicyclic ketone compounds and methods of use thereof
EP3694858B1 (en) 2017-10-11 2023-01-11 F. Hoffmann-La Roche AG Bicyclic compounds for use as rip1 kinase inhibitors

Also Published As

Publication number Publication date
EP3704097C0 (en) 2023-10-25
AU2018360270A1 (en) 2020-03-26
PE20211247A1 (es) 2021-07-13
US20190127382A1 (en) 2019-05-02
SG11202002877RA (en) 2020-04-29
KR20200083515A (ko) 2020-07-08
WO2019086494A1 (en) 2019-05-09
MA50503A (fr) 2020-09-09
CL2020001062A1 (es) 2020-08-21
AR113811A1 (es) 2020-06-10
MX2020003451A (es) 2020-08-03
EP3704097A1 (en) 2020-09-09
CA3078688A1 (en) 2019-05-09
US11072617B2 (en) 2021-07-27
JP2021501183A (ja) 2021-01-14
US20230002391A1 (en) 2023-01-05
PH12020550537A1 (en) 2021-03-22
RU2020115915A (ru) 2021-12-01
CN111278809A (zh) 2020-06-12
BR112020008446A2 (pt) 2020-12-29
CR20200168A (es) 2020-07-12
IL273847A (en) 2020-05-31
RU2020115915A3 (es) 2022-05-06
EP3704097B1 (en) 2023-10-25
TW201922748A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CO2017011851A2 (es) Compuestos novedosos
CR20170573A (es) Lactamas bicíclicas y métodos de uso de las mismas
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
UY35293A (es) Isotiazoles sustituidos con amino
CL2020000101A1 (es) Compuestos de cetonas bicíclicas y métodos de uso de los mismos.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CO2018007663A2 (es) Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CL2018002368A1 (es) Formulaciones de oritavancina
CR20150641U (es) Composiciones farmacéuticas
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
UY37032A (es) Compuestos de heteroarilbenzimidazol
CR20150593A (es) Potenciador de inhibidores del homólogo de zeste